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Abstract
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n =
270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The
composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21
and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in
the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for
recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular
disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47).
CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events
after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major
bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical
outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an
advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.
Introduction
Polycythemia vera (PV), essential thrombocythemia
(ET), and primary myelofibrosis (PMF) are chronic mye-
loproliferative neoplasms (MPNs) characterized by clonal
expansion of an abnormal haematopoietic stem/pro-
genitor cell1 that harbours somatic gene mutations: JAK2
mutations define PV, while mutations of calreticulin
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(CALR) and thrombopoietin receptor (MPL) are specific
to the majority of JAK2 un-mutated ET and PMF2.
The natural history of these disorders is marked by
venous and arterial thrombosis, hemorrhagic complica-
tions, and a propensity to transform into myelofibrosis
(MF) and acute myeloid leukaemia (AML)2. Arterial
thrombosis accounts for approximately two thirds of all
major thrombotic events and represents a major cause of
mortality. In particular, ischemic stroke (IS) and transient
ischemic attack (TIA) are most prevalent in comparison
with acute myocardial infarction (AMI) and peripheral
artery occlusions3,4.
The incidence of ischemic cerebrovascular events
(ICVE) in MPN has been evaluated in a few studies. In a
cohort of 1638 PV patients enrolled in the European
Collaborative Low-dose Aspirin Polycythemia Vera
(ECLAP) study5 and in a recent large observational study,
including 1545 patients with JAK2-mutated PV6, the
incidence was 1.2 and 0.9 per 100 patient-years, respec-
tively. Similar findings were reported in ET patients. In
the PT-17 and in the ANA-HYDRET8 trials, the incidence
of ICVE was 1.2 and 1.7 per 100 patient-years, respec-
tively. These rates are approximately 10-fold higher than
in the general population, where the incidence is esti-
mated at 0.17 per 100 patient-years9.
Patients with MPN presenting with any type of venous
and arterial thrombosis or with a previous history of
cardiovascular (CV) events are labelled at high-risk for
recurrences, and cytoreduction in addition to antith-
rombotic drugs is recommended to reduce the rate of
recurrence10–12, although both the modalities of treat-
ment and the effectiveness on prevention of recurrences
have been scarcely explored. In a single retrospective
study, recurrence after TIA/stroke in MPN was estimated
at 1.18 per 100 patient-years13. This figure is even lower
than in the general population in which the long-term
incidence of recurrent IS varies from 2.0 to 3.0 per 100
patient-years14–17. Moreover, there is no controlled study
assessing whether the incidence of major bleeding in
MPN patients, eventually attributable to the use of
antithrombotic drugs, is higher than in the general
population owing the intrinsic bleeding characteristics of
MPNs3.
Therefore, considering the scarcity of data on the ben-
efit/risk ratio of prophylaxis of recurrence with antith-
rombotic and cytoreductive drugs after those life-
threatening complications, we launched an international
investigator-driven retrospective cohort study called the
Preventing Ischaemic Stroke in Myeloproliferative Neo-
plasms (PRISM) study with three purposes: to describe
the clinical profile at presentation of TIA/IS in con-
temporary PV, ET, and PMF patients; to evaluate the
short and long-term outcomes beyond the acute phase,
also in comparison with the general, non-MPN popula-
tion; and to refine the risk assessment for recurrences and
CV mortality.
Patients and methods
Study patients
A retrospective cohort study was conducted across
22 sites of 5 countries in the European Union and Israel
within the European Leukaemia Network (ELN) in
patients with a diagnosis of MPN according to the WHO
2008 criteria, after approval of the ethic committees (ECs)
(primary approval by the central EC of the coordinating
centre was obtained on 12 May 2016).
The participants were asked to identify, among all
patients with MPN, those who had suffered from TIA and
IS in the period from January 1, 2005 to December 31,
2015. The index event had to be concurrent with, or in the
2 years before, MPN diagnosis, or occurring during the
course of a previously diagnosed MPN disease.
Stroke was defined as an episode of acute neurological
dysfunction caused by focal cerebral ischaemia, based on
objective imaging techniques (computed tomography
scan or magnetic resonance imaging scan) and clinical
evidence of cerebral focal ischemic injury based on
symptoms of any duration. TIA was defined as a transient
episode of neurological dysfunction caused by focal brain
ischemia, presenting with a unilateral motor or sensory
deficit, speech deficit, haemianopsia or monocular blind-
ness, lasting less than 24 h and without evidence of acute
infarction on neuroimaging. Patients with hemorrhagic
stroke (both intra-parenchymal and subarachnoid hae-
morrhage), cerebral venous thrombosis, and iatrogenic
stroke (i.e., strokes related to neuro-endovascular proce-
dures or coronary angiography) were excluded. Two
neurologists (VDL and BC) independently reviewed the
diagnostic criteria employed to record TIA and IS
patients.
Treatment in the acute phase was delivered by stroke
specialists after consulting with haematologists who, after
the acute event, took care of these patients during the
follow-up.
Each centre reported patients’ information by data input
into an electronic database developed to record all study
data after de-identification of the patients with an alpha-
numeric code to protect personal privacy. For each
patient, the following information was recorded: demo-
graphic data, WHO diagnosis, type of ICVE, method of
objective diagnosis, presence of microvascular dis-
turbances or constitutional symptoms, mutation status,
the results of the laboratory investigation for inherited or
acquired thrombophilia (that is, deficiency of antitrombin,
protein C, protein S, factor V Leiden, prothrombin
G20210A, increased levels of factor VIII,
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hyperhomocysteinemia, lupus anticoagulant, antic-
ardiolipin, and anti-beta2-glycoprotein I antibodies), full
blood count at diagnosis and at thrombosis, presence of
CV risk factors (that is, history of previous thrombosis
before the index event, smoking habit, hypertension and
dyslipidaemia, diabetes, congestive heart failure) and risk
factors for cardiogenic embolism or vascular embolism
(that is, atrial fibrillation, patent foramen ovale, valvular
heart disease, significant carotid artery stenosis). Micro-
vascular disturbances included erythromelalgia, scintil-
lating scotoma, pulsatile headache, dizziness, and tinnitus.
Diagnosis of microvascular disturbances, as well as of
TIA, was accepted only in the presence of unequivocal
medical documentation.
Data regarding cytoreductive or antithrombotic treat-
ment after index IS or TIA, duration of the treatment and
reasons for discontinuation of the treatments were
recorded. Finally, follow-up data concerning novel
thrombotic events, bleeding complications, MPN hae-
matologic evolution, and death were also recorded.
Outcomes after the index event
Recurrent IS was defined as a focal neurologic deficit of
any duration with evidence at neuroimaging of brain
ischemia located in an area not corresponding to the
lesion(s) of the index stroke. Recurrent TIA was defined
as a novel transient neurologic dysfunction (duration of
less than 24 h) without evidence of infarction on brain
imaging. Two neurologists (VDL and BC) independently
reviewed and validated diagnoses of novel TIA and IS
after the index event.
Other arterial or venous thrombotic events that occur-
red after the index event were recorded only if objectively
documented. Arterial recurrences besides ICVE included
AMI, unstable angina pectoris and peripheral arterial
thrombosis. Objectively established deep venous throm-
bosis (DVT) of the legs and pulmonary embolism (PE),
DVT of the arm, occlusion of cerebral or abdominal veins,
thrombosis of the great saphenous vein of the leg objec-
tively diagnosed with ultrasonography, and retinal vein
thrombosis were also computed after the index TIA/IS.
Major bleeding was defined according to the criteria of
the International Society on Thrombosis and Haemos-
tasis18 and included fatal events or events occurring in a
critical area such as an intracranial, intra-spinal, intrao-
cular, retroperitoneal, intra-articular or pericardial, or
intramuscular event. Bleeding was also defined as major
when it occurred in non-critical areas (epistaxis, others)
and was associated with a reduction of ≥2 g/dL in the
haemoglobin concentration and/or necessitated transfu-
sion of ≥2 blood units. MPN evolution into MF and/or
AML was diagnosed according to the current guide-
lines10–12.
Statistical methods
For continuous variables, the median and the 5th–95th
percentiles or range are provided and non-parametric
tests for the difference in medians between groups were
performed. Categorical variables were summarized by
counts and percentages, and groups were compared with
a Chi-squared test or Fisher’s exact test where appro-
priate. The annual incidence rate of any event that
occurred during the follow-up was calculated by dividing
the number of events by the total number of patient-years.
A composite CV outcome was defined including TIA,
non-fatal IS, non-fatal AMI, and CV death, whichever
occurred first. The cumulative probability of experiencing
a specific outcome during follow-up was estimated by the
competing risks method19. With this approach, a subject
was assumed to experience the outcome only once, and
the overall incidence at a given time was split into the sum
of the cause-specific cumulative incidences.
Finally, the Cox proportional hazard regression was
used to estimate the hazard ratio (HR) and 95% con-
fidence interval (CI) for the association between any
potential risk factor and time of each outcome onset.
Starting with all candidate variables (i.e., those listed in
Table 1 as well as antithrombotic or cytoreductive treat-
ment), backward selection was used to test whether the
deletion or retention of each variable improved the model,
repeating this process until no further improvement was
possible. For all hypotheses tested, two-tailed p-values less
than 0.05 were considered significant.
Results
Clinical and laboratory features of the cohort
The initial cohort suitable for the study consisted of
5102 MPN patients diagnosed from January 2005 through
December 2015. Out of 615 patients recorded by centres,
18 were excluded: two with hemorrhagic stroke, and 16
with TIA or IS not considered as MPN-related because
occurred before 2 years preceding the diagnosis of MPN,
leaving a total of 597 MPN patients with documented TIA
(n= 270) or IS (n= 327).
The majority were over 60 years of age at the time of the
index event; the frequency of the JAK2 V617F mutation
was 100% in PV patients and 82% and 76% in ET and PMF
patients, respectively.
IS was documented more frequently than TIA at diag-
nosis, while TIA occurred in 63% of the cases during the
course of MPN disease (Table 1). The distribution of PV,
ET and PMF and baseline blood counts were similar in IS
and TIA groups; patients with IS had more often a history
of remote vascular events (more than 2 years before MPN
diagnosis), active smoking, dyslipidaemia and atrial
fibrillation, while TIA cases had a significantly higher
history of microvascular disturbances (Table 1).
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Table 1 Patient demographic and clinical characteristics
N Index stroke (N = 327) Index TIA (N = 270) p-value
Male/female—n (%) 597 141/186 (43/57) 105/165 (39/61) 0.296
Age at index event—median (5th–95th percentile) 597 69 (37–84) 68.5 (40–83) 0.970
MPN characteristics
MPN diagnosis—n (%) 597 0.201
Polycythemia vera 107 (33) 77 (29)
Essential thrombocythemia 174 (53) 163 (60)
Myelofibrosis 46 (14) 30 (11)
Mutational status—n (%) 553 0.490
JAK2 mutation/exon 12 270 (89) 211 (85)
CALR mutation 18 (6) 21 (8)
MPL mutation 4 (1) 6 (2)
Triple negatives 12 (4) 11 (4)
Data at index event
Imaging—n (%) 578
Computed tomography scan 203 (64) 177 (68) 0.236
Magnetic resonance imaging scan 116 (36) 82 (32)
Blood cells values—median (5th–95th percentile)
Hemoglobin (g/dL) 433 14.0 (10.4–17.9) 14.2 (10–17.6) 0.401
Hematocrit (%) 418 43.0 (32.0–55.6) 44.0 (34.0–54.0) 0.238
White blood cells count (×109/L) 440 9.1 (4.5–20.0) 8.9 (5.0–17.1) 0.387
Platelets count (×109/L) 459 523 (204–1067) 551 (255–1103) 0.206
Index event heralding MPN diagnosisa—n (%) 597 149 (46) 101 (37) 0.044
Index event after MPN diagnosis—n (%) 178 (54) 169 (63)
Years from MPN diagnosis to index event—median (5th–95th percentile) 347 4.37 (0.26–22.2) 4.48 (0.35–16.3) 0.958
Cardiovascular risk factors
History of remoteb arterial and/or venous thrombosis—n (%) 597 76 (23) 44 (16) 0.035
History of remoteb cerebrovascular thrombosis—n (%) 597 25 (8) 16 (6) 0.408
Active smoking 597 82 (25) 46 (17) 0.017
Hypertension 597 187 (57) 140 (52) 0.192
Dyslipidemia 597 91 (28) 55 (20) 0.035
Diabetes 597 38 (12) 30 (11) 0.845
Atrial fibrillation 597 23 (7) 10 (4) 0.079
Other cardiogenic embolismsc 597 42 (13) 25 (9) 0.167
Microvascular disturbancesd 597 77 (24) 83 (31) 0.048
Presence of thrombophilia—n (%) 238 54 (43) 40 (36) 0.307
Inherited thrombophiliae 16 (13) 13 (12) 0.835
Hyperhomocysteinemia 30 (24) 18 (16) 0.155
Antiphospholipid antibodiesf 13 (10) 12 (11) 0.885
aIndex events (ischemic stroke and TIA) occurred within a maximum of two years before the diagnosis of MPN or as heralding manifestation of MPN
bAnamnestic thrombosis occurred two years or more before the diagnosis of MPN
cOther embolisms or cardiogenic embolisms include patent foramen ovale, valvular heart disease (mitral stenosis, artificial valves), significant carotid artery stenosis,
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Even though thrombophilia had a similar occurrence in
the two groups, a trend for a greater frequency of inher-
ited abnormalities was seen in patients less than 40 years
(25%) than in the other age categories (13% and 9% for age
40–60 years and over 60 years, respectively; p= 0.094).
Almost all patients received cytoreductive therapy
(hydroxyurea in the large majority) and long-term treat-
ment with low-dose aspirin particularly after TIA (p<
0.0001), while oral anticoagulants were more frequently
prescribed after stroke (p< 0.0001) (Table 2).
Single and composite CV outcomes
During a total follow-up time of 2347 years after the
index event (median 4.2, range 0–11.9), 113 patients
(18.9%) experienced an incident thrombosis, 76% in
arterial and 24% in venous sites (Table 3). The incidence
rates of overall de-novo thrombosis and recurrent ICVE
were 4.81 (95% CI 3.91–5.78) and 2.59 (95% CI 1.98–3.33).
The cumulative incidence of single and composite
outcome is reported in Table 4. At one year, the cumu-
lative incidence of the composite CV outcome was lower,
though not significant, after TIA (4.21%) than after IS
(7.14%) (p= 0.13), but the frequency resulted similar after
5 years (18.9 and 19.2%). The lower frequency of a com-
posite outcome in the first year after TIA was due to the
absence of incident cases of strokes and AMI, while
recurrent TIA and AMI progressively increased at 5 years
to 12% and 3.74% of patients, respectively. In contrast,
after the index stroke, cerebral events including TIA and
new IS occurred earlier and progressively increased.
However, after 5 years, the two groups showed a similar
cumulative incidence of ischemic cerebrovascular recur-
rences (13.2% and 12.3% after TIA and stroke, respec-
tively), although the occurrence of the single outcome was
different.
In TIA patients, recurrent TIA contributed to 63% of
the composite CV outcome; in contrast, the single out-
comes after IS (CV mortality, IS, and TIA) contributed
equally to the estimate of the composite outcome; in
particular, after 5 years, CV deaths were more frequent
than after TIA (7.18 and 2.14% respectively, p= 0.011).
Figure 1 offers a graphic representation of the cumulative
incidence of the specific outcomes contributing to the
composite CV outcome after the two index events.
Venous thrombosis showed a higher cumulative inci-
dence in the first year after stroke than after TIA (p= 0.03
and p= 0.02 at 3 and 6 months, respectively), but these
rates were similar after 5 years (3.68% and 4.60%,
respectively).
The overall mortality after 1 year was comparable in the
two groups (2.84% vs. 1.92%) and was due to CV com-
plications in 88% after stroke and 39% after TIA. After 5
years, deaths for CV causes decreased to 35% after stroke
and to 21% after TIA. Other causes of death were due to
MF, acute leukaemia, solid tumour, infections, or hae-
morrhages (Table 3).
The significant variables associated with arterial events,
identified by backward selection for each specific outcome
starting from the full model including all explanatory
variables, are presented in Fig. 2. Independent prognostic
factors of incident recurrent TIA were a previous index
TIA, history of remote TIA and microvascular dis-
turbances. Likewise, new incident ISs were predicted by
an index stroke, particularly occurring after MPN diag-
nosis. In the IS group, arterial hypertension emerged as an
independent risk factor. Of note, cytoreductive treatment
was a strong protective factor capable of reducing the risk
of new IS in 76% of patients. The only prognostic risk
factor for AMI was a prior history of remote arterial and
Table 2 Medication use after the index stroke or TIA
Index stroke
(N = 313a)
Index TIA (N
= 264a)
p-value
Antithrombotic treatment
None 14 (4) 10 (4) 0.681
Antiplatelet agent 247 (79) 239 (91) <0.0001
Single agent (ASA or
other)
235 (75) 230 (87) <0.0001
Double agent (ASA +
other)
12 (4) 9 (3) 0.786
Anticoagulant agent 51 (16) 14 (5) <0.0001
VKA 48 (15) 13 (5) <0.0001
DOAC 3 (1) 1 (<1) 0.629
Heparin 1 (<1) 1 (<1) 0.904
Cytoreductive treatment
None 32 (10) 25 (9) 0.762
Phlebotomy 2 (<1) 8 (3) 0.049
Hydroxyurea 248 (79) 204 (77) 0.569
Alone 224 (72) 193 (73) 0.680
In combination 24 (8) 11 (4) 0.079
Anagrelide 3 (1) 15 (6) 0.001
Interferon 11 (4) 6 (2) 0.380
Ruxolitinb 5 (2) 3 (1) 0.733
Otherb 12 (4) 3 (1) 0.063
Overall, 503 patients (87.2%) received either cytoreductive and antithrombotic
treatments; 50 patients (8.7%) received only antithrombotic treatment (and no
cytoreductive treatment), 17 patients (2.9%) received only cytoreductive
treatment (and no antithrombotic treatment), and 7 patients (1.2%) received
neither cytoreductive nor antithrombotic treatments
ASA acetylsalicylic acid, VKA vitamin K-antagonist, DOAC direct oral antic-
oagulant
aTwenty out of 597 patients (3%) have missing information on treatments after
the index event
bOther cytoreductive treatment includes pipobroman, busulphan, P32
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Table 3 Overall incidence of major events after the index stroke or TIA
Index stroke (N = 327) Index TIA (N = 270) p-valuea
Events, n
(%)
Patient-
years
Incidence rate % pt-
yrs (95% CI)
Events, n
(%)
Patient-
years
Incidence rate % pt-
yrs (95% CI)
Thrombotic events, n =
113
54 (17) 1179 4.41 (3.36–5.79) 59 (22) 1168 4.97 (3.84–6.42) 0.5350
Arterial thrombosis,
n = 86
38 (12) 1228 3.10 (2.25–4.25) 48 (18) 1199 3.92 (2.94–5.22) 0.2814
Unstable angina
pectoris
1 (0.3) 1 (0.4)
Acute myocardial
infarction
4 (1.2) 1308 0.31 (0.11–0.82) 10 (3.7) 1350 0.67 (0.35–1.28) 0.1982
TIA+ 13 (4.0) 1290 1.01 (0.59–1.74) 29 (10.7) 1243 2.33 (1.62–3.36) 0.0098
Stroke+ 15 (4.6) 1291 1.6 (0.70–1.93) 4 (1.5) 1378 0.29 (0.11–0.77) 0.0079
Peripheral artery
thrombosis
4 (1.2) 4 (1.5)
Splenic infarction 1 (0.3) 0 (0)
+TIA + stroke, n = 61 28 (9) 1255 2.23 (1.54–3.23) 33 (12) 1240 2.66 (1.89–3.74) 0.4959
Venous thrombosis,
n = 27
16 (5) 1278 1.10 (0.65–1.85) 11 (4) 1349 0.82 (0.45–1.47) 0.4709
DVT of the legs 5 (1.5) 7 (2.6)
DVT of the legs + PE 3 (0.9) 2 (0.7)
Pulmonary embolism 2 (0.6) 0 (0)
Superficial vein
thrombosis
2 (0.6) 1 (0.4)
Hepatic vein
thrombosis
1 (0.3) 0 (0)
Splanchnic vein
thrombosis
2 (0.6) 0 (0)
Cerebral vein
thrombosis
1 (0.3) 0 (0)
Retinal vein
thrombosis
0 (0) 1 (0.4)
Major bleeding, n = 25 15 (5) 1299 1.08 (0.64–1.82) 10 (4) 1355 0.74 (0.40–1.37) 0.3681
Intracranial bleeding 6 (1.8) 2 (0.7)
Gastrointestinal
bleeding
3 (0.9) 5 (1.9)
Other sites 6 (1.8) 3 (1.1)
Evolution to MF, n = 19 9 (3) 1308 0.69 (0.36–1.32) 10 (4) 1356 0.66 (0.35–1.28) 0.9407
Evolution to AML, n = 17 6 (2) 1326 0.45 (0.20–1.01) 11 (4) 1380 0.80 (0.44–1.44) 0.2713
Second neoplasia, n = 51 26 (8) 1273 2.04 (1.39–3.00) 25 (9) 1341 1.79 (1.20–2.67) 0.6435
Breast 5 (1.5) 5 (1.9)
Gastrointestinal/liver 3 (0.9) 5 (1.9)
Kidney 0 (0) 2 (0.7)
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venous thrombosis, while CV death was predicted by a
previous index IS, age over 60 years, and by the index
event occurring after MPN diagnosis.
Bleeding
Major bleeding occurred in 25 patients (4%), corre-
sponding to an incidence rate of 0.9 per 100 patient-years
(Table 5), with no difference between patients receiving
antiplatelet drugs or oral anticoagulants. Of note, the
eight cases experiencing cerebral bleeding were receiving
single agent aspirin while no events in critical areas were
seen in patients receiving oral anticoagulants. Among the
risk factors, univariate analysis showed that age over 75
year was significantly associated with a risk of major
haemorrhages (HR= 2.39, 95% CI 1.07–5.34, p= 0.035);
however, in the multivariate model, corrected by the
already mentioned risk factors, this effect was reduced to
a trend (p= 0.074), while significant factors were the
history of remote thrombosis (HR= 2.51, 95% CI
1.05–5.96, p= 0.038) and the thrombotic complications
arising after MPN diagnosis (HR= 2.99, 95% CI
1.08–8.29, p= 0.035).
Discussion
The large cohort of MPN patients included in the
PRISM study represents, to the best of our knowledge, the
most updated and comprehensive clinical epidemiological
picture of how patients with cerebrovascular ischemia are
managed in specialized haematological centres. In this
large cohort, we obtained for the first time an accurate
and comprehensive picture of the history of incident
recurrences, CV events, and death over long-term follow-
up after the occurrence of an index TIA and IS.
At index TIA and IS presentation, patients had atrial
fibrillation in a minority of cases (4 and 7%) compared
with the general population (11–18% in TIA cases and
20–30% in IS cases, respectively)20–23; dyslipidemia and
diabetes were also less frequent, accounting for approxi-
mately 50% of those found in non-MPN patients20–23.
Therefore, the association of these comorbidities with
TIA and IS events appears less evident in MPN than in
non-MPN patients, suggesting that the condition of
thrombophilia due to the underlying disease plays a major
role via constitutive activation of the haemostatic system4.
We underline the high frequency of JAK2V617F mutated
patients in our cohort, confirming the significant influ-
ence of the JAK2V617F mutation in the pathogenesis of
thrombosis in these clonal diseases4. Of interest, a great
proportion of the patients presenting with an index TIA
and IS had a prior history of microvascular disturbances
underscoring their possible significance as predictors of
major thrombosis in MPN24.
To prevent recurrences and CV mortality, the patients
in this study had received aspirin, vitamin K antagonists
(VKA) or direct oral anticoagulants as recommended for
the general population25, in addition to cytoreductive
drugs according to the MPN treatment guidelines10–12.
Table 3 continued
Index stroke (N = 327) Index TIA (N = 270) p-valuea
Events, n
(%)
Patient-
years
Incidence rate % pt-
yrs (95% CI)
Events, n
(%)
Patient-
years
Incidence rate % pt-
yrs (95% CI)
Lung 1 (0.3) 1 (0.4)
Lymphoma/CLL 3 (0.9) 2 (0.7)
Prostate/bladder 5 (1.5) 2 (0.4)
Skin 4 (1.2) 4 (1.5)
Other 5 (1.5) 4 (1.5)
Death, n = 102 61 (19) 1327 4.37 (3.38–5.66) 41 (15) 1381 2.97 (2.19–4.03) 0.0572
Cardiovascular 26 (8.0) 1327 1.73 (1.15–2.61) 8 (3.0) 1381 0.58 (0.29–1.16) 0.0050
Infection 4 (1.2) 4 (1.5)
MF 1 (0.3) 1 (0.4)
AML 6 (1.8) 8 (3.0)
Second neoplasia 4 (1.2) 7 (2.6)
Hemorrhage 0 (0) 1 (0.4)
Unknown 20 (18.7) 12 (4.4)
aTests for differences in incidence rates
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At one year after the TIA index event, 51 outcomes (8
deaths from CV causes, 4 IS, 10 AMI, and 29 TIA), cor-
responding to a composite cumulative incidence of 4.21%.
This compares favourably with a contemporary cohort of
patients with TIA or minor stroke recruited from the
general population, in which the composite outcome at
one year was 6.2%22. However, in contrast to the general
population, the single outcomes after TIA presented with
Fig. 1 Cumulative incidence of TIA, non-fatal stroke, non-fatal AMI, and cardiovascular (CV) death by type of index event (panel a: index
TIA; panel b: index stroke). The cumulative probability of experiencing a specific outcome was estimated by the competing risks method
Fig. 2 Hazard ratio (and 95% confidence interval) for the association between significant risk factors and time of CV outcomes onset.
Estimates from multivariate Cox proportional hazard models with competitive risks method. Significant (p < 0.05) hazard ratio (HR) estimates kept by
backward selection beginning from the full model on all explanatory variables are plotted
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a different incidence. It is remarkable that among patients
with TIA, no IS occurred in the first 2 years and that
strokes occurred after 5 years in only 1.24% of cases.
These estimates are lower than in contemporary non-
MPN patients with TIA, in whom strokes occurred in
4.4–5.1% of patients after 1 year14,15,22, and 12–13.2% after
5 years14,15. In contrast, while strokes were rare events,
the cumulative incidence of new TIA episodes progres-
sively increased year by year and reached a 12% incidence
after 5 years, with a 10% overall mortality rate. On the
other hand, after the index IS, new strokes occurred with
a cumulative incidence lower than in the general popu-
lation: after 1 and 5 years, it was 2.03 and 6.52% vs
11.1–12% and 26.4% of non-MPN patients, respec-
tively16,23. As expected, in comparison with TIA, overall
mortality after stroke was doubled (20.4%), due to CV
causes in 35% of cases. As regards risk factors for recur-
rent events, TIA or IS patients tended to replicate the first
manifestation (HR for recurrent TIA and recurrent IS 2.4
and 4.4, respectively); moreover recurrent TIA was sig-
nificantly anticipated by microvascular symptoms (HR
2.3), whereas recurrent stroke was associated with
hypertension (HR 4.2). The use of cytoreductive drugs
was a strong protective factor and decreased the rate of
recurrent IS by 76%. Notably, the occurrence of the index
events in the course of follow-up after diagnosis of MPN,
in spite of antithrombotic prophylaxis and cytoreductive
drugs, was identified as a strong prognostic factor for IS
and CV death.
The different clinical course of recurrences after index
TIA or IS could reflect a non-univocal pathogenesis of the
two clinical phenotypes. We speculate that in TIA, there
is a prominent role of haemostatic alterations character-
ized by an ongoing process of platelet activation, platelet
aggregation and abnormal platelet-endothelial
interactions, producing endothelial cell activation and
transient damage in microvascular districts26–29. This
haemostatic perturbance, when combined with hyper-
tension, was found to be independently associated with
recurrences in patients with IS, reflecting a condition
leading to a higher frequency of more severe cerebral
ischemic events.
An important outcome that should be evaluated after
TIA and stroke is myocardial infarction. The frequency at
5 years of AMI was 3.74% and 1.80% in TIA and stroke,
respectively, which are estimates comparable to the gen-
eral population30. Finally, the cumulative incidence of
venous thromboembolism (VTE) was higher after stroke
in the first year, while at 5 years it was comparable after
TIA and stroke (3.68% and 4.60%, respectively). This
latter estimate is strikingly lower than that reported in a
population-based study in which the cumulative incidence
of VTE after stroke was as high as 15% at 3 months after
the event, with a subsequent slow increase up to
approximately 40% at 5 years after a stroke31. All in all, the
cumulative incidence of the composite outcome, includ-
ing ICVE, AMI, and CV deaths, was the same (19%) at 5
years after both an index TIA and IS, even though the
single outcomes were differently represented.
The limitations of our study are those of a retrospective
observational study. Case ascertainment, however, was
based on objective imaging in almost the totality of cases
(97%) and confirmation of the diagnosis by experienced
stroke clinicians who took care of the patients in the acute
phase. The collection of the data was made by expert
haematologists and every effort was made to minimize
missing data and incomplete follow-up; as a result, no
data concerning traditional CV risk factors were missing,
and no patient was lost to follow-up. The patients were
selected from an MPN database of over 5000 patients
Table 5 Incidence of major bleeding according to antithrombotic therapy
N
(%)
Total, N = 597 % pts/year
(95% CI)
Antiplatelet agents, n = 486 % pts/year
(95% CI)
Anticoagulant agents, n = 65 % pts/
year (95% CI)
p-
valuea
Major bleeding 25
(4)
0.90 (0.61–1.35) 0.94 (0.61–1.44) 0.79 (0.20–3.16) 0.980
CNS bleeding 8
(1.3)
0.30 (0.15–0.59) 0.35 (0.18–0.70) 0 (0) 0.426
GI bleeding 8
(1.3)
0.26 (0.12–0.55) 0.26 (0.12–0.59) 0.40 (0.06–2.81) 0.674
Muscle
hematoma
5
(0.8)
0.19 (0.08–0.45) 0.18 (0.07–0.47) 0.39 (0.05–2.77) 0.497
Epistaxis 4
(0.6)
0.15 (0.06–0.40) 0.13 (0.04–0.41) 0 (0) 0.726
CNS cerebral nervous system, GI gastrointestinal
aTests for differences in incidence rate between antiplatelet agents and anticoagulant agents groups
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diagnosed by expert centres in the last decade, so that our
results can be generalized to the overall contemporary
population of the MPN patients.
At least three reasons may account for the inferior rate
of CV complications after TIA or strokes in MPN com-
pared to the general population: first, atrial fibrillation is
recognized as a risk factor for recurrent ICVE32, and this
condition was low in our patient population; second, we
speculate about a better control and adherence to the
prescribed drugs (antithrombotic, anti-hypertensive, sta-
tins, and antidiabetics) due to the more frequent follow-
up visits needed to monitor chemotherapy; and third, we
underline the antithrombotic efficacy of hydroxyurea on
MPN-associated risk factors33,34. The antithrombotic
effect of hydroxyurea may recognize additional mechan-
isms of action besides myelosuppression, including qua-
litative changes in leukocyte function, decreased
expression of endothelial adhesion molecules, and
enhanced nitric oxide generation35,36.
The favourable risk-benefit profile of therapy in the
prevention of CV events was obtained without enhancing
the risk of major bleeding, which had an incidence similar
to the general population receiving long-term antiplatelet
secondary prophylaxis37.
Even though the recurrent events after TIA and stroke
showed an inferior incidence compared to the non-MPN
population, a residual risk of new TIA and strokes
remained, and future studies should be designed to test
new antithrombotic therapy and perhaps include new
cytoreductive drugs.
However, the long-term observation of this cohort
suggests some considerations that may have practical
clinical relevance: (a) MPN patients with a previous ICVE
are prone to recurrence including also other major CV
events; (b) the observed advantage for recurrence when
compared to the general population, is likely due to a
strict adherence to the recommended treatment options
for long-term treatment of MPN patients with thrombo-
sis10–12, based on antithrombotic treatment, cytoreduc-
tion, and phlebotomies; (c) cytoreduction with
hydroxyurea resulted particularly effective in patients with
IS, who are at higher risk of CV death; (d) although the
incidence of major bleeding was aligned with that
expected in the general population under anticoagulants,
a prudent use of aspirin may be suggested in patients with
a previous long history of treatments for thrombosis and
with age over 75 years, given the enhanced hemorrhagic
risk37.
In conclusion, current antithrombotic therapy and
cytoreductive drugs after an index TIA and stroke in
MPN lead to a reduction of cardio-vascular recurrences
and mortality in a remarkable proportion of patients,
resulting even superior to that in the general population.
Overall, the benefit-risk profile of treatment with
antithrombotic treatment and cytoreduction in these
neoplastic disorders appears favourable, but some cate-
gories of patients with TIA and stroke occurring after
MPN diagnosis might require special strategies, to be
assessed in future studies.
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